Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020).
starting_dose
String
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site.
preparations
String
28 mg/device (each dose uses 2 devices)
fda_max
String
84 mg per session
pill_id
Text
routes
List of String, delimiter: ,
Intranasal (under direct medical supervision)
onset
String
Within hours of first administration
duration
String
Acute effect ~24 hours; cumulative effect builds with repeated dosing
